View More View Less
  • 1 Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, Általános Orvostudományi Kar Belgyógyászati Intézet, Hematológiai Tanszék Debrecen Pf. 20 4012
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

A Waldenström-macroglobulinaemia ritka, indolens lefolyású B-sejt-eredetű lymphoproliferativ kórkép. A tumorsejtek monoklonális IgM proteint termelnek, a diagnózis a monoklonális IgM és a csontvelőt infiltráló lymphoid és lymphoplasmacytoid sejtek kimutatásán alapul. A klinikai tünetek (hyperviscositas, neuropathia, anaemia stb.) a monoklonális IgM és a csontvelői (ritkábban extramedulláris) érintettség következményei. A korábbi alkilálószereken alapuló terápiát a purinanalógok, a rituximab, a bortezomib alkalmazása, illetve ezek kombinációi váltották fel. Bővülnek a tapasztalatok az autológ és az allogén őssejt-transzplantációval is. A szerzők saját tapasztalataik mellett áttekintik a betegséggel kapcsolatos ismereteket és a jelenlegi terápiás lehetőségeket. Orv. Hetil., 2013, 154(50), 1970–1974.

  • Gertz, M.: Waldenström macroglobulinemia: my way. Leuk. Lymphoma, 2013, 54, 464–471.

    Gertz M. , 'Waldenström macroglobulinemia: my way ' (2013 ) 54 Leuk. Lymphoma : 464 -471.

  • Ghobrial, I. M.: Are you sure this is Waldenström macroglobulinemia? ASH, Education Program Book, 2012, 586–594.

    Ghobrial I. M. , '', in Are you sure this is Waldenström macroglobulinemia? , (2012 ) -.

  • Owen, R. G., Treon, S. P., Al-Katib, A., et al.: Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s macroglobulinemia. Semin. Oncol., 2003, 30, 110–115.

    Al-Katib A. , 'Clinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s macroglobulinemia ' (2003 ) 30 Semin. Oncol. : 110 -115.

    • Search Google Scholar
  • Kastritis, E., Kyrtsonis, M-C., Hatjiharissi, E., et al.: No significant improvement in the outcome of patients with Waldenström’s macroglobulinemia treated over the last 25 years. Am. J. Hematol., 2011, 86, 479–483.

    Hatjiharissi E. , 'No significant improvement in the outcome of patients with Waldenström’s macroglobulinemia treated over the last 25 years ' (2011 ) 86 Am. J. Hematol. : 479 -483.

    • Search Google Scholar
  • Johnson, S. A., Birchall, J., Luckie, C., et al.: Guidelines on the management of Waldenström macroglobulinaemia. Br. J. Haematol., 2006, 132, 683–697.

    Luckie C. , 'Guidelines on the management of Waldenström macroglobulinaemia ' (2006 ) 132 Br. J. Haematol. : 683 -697.

    • Search Google Scholar
  • Ngo, V. N., Young, R. M., Schmitz, R., et al.: Oncogenically active MYD88 mutations in human lymphoma. Nature, 2011, 470, 115–119.

    Schmitz R. , 'Oncogenically active MYD88 mutations in human lymphoma ' (2011 ) 470 Nature : 115 -119.

    • Search Google Scholar
  • Morel, P., Duhamel, A., Gobbi, P., et al.: International prognostic scoring system for Waldenström macroglobulinemia. Blood, 2009, 113, 4163–4170.

    Gobbi P. , 'International prognostic scoring system for Waldenström macroglobulinemia ' (2009 ) 113 Blood : 4163 -4170.

    • Search Google Scholar
  • Owen, R. G., Kyle, R. A., Stone, M. J., et al.: Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br. J. Haematol., 2012, 160, 171–176.

    Stone M. J. , 'Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop ' (2012 ) 160 Br. J. Haematol. : 171 -176.

    • Search Google Scholar
  • Dimopoulos, M. A., Alexanian, R.: Waldenstrom’s macroglobulinemia. Blood, 1994, 83, 1452–1459.

    Alexanian R. , 'Waldenstrom’s macroglobulinemia ' (1994 ) 83 Blood : 1452 -1459.

  • Dimopoulos, M. A., O’Brien, S., Kantarjian, H., et al.: Fludarabine therapy in Waldenström’s macroglobulinemia. Am. J. Med., 1993, 95, 49–52.

    Kantarjian H. , 'Fludarabine therapy in Waldenström’s macroglobulinemia ' (1993 ) 95 Am. J. Med. : 49 -52.

    • Search Google Scholar
  • Dhodapkar, M. V., Jakobson, J. L., Gertz, M. A., et al.: Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglubulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood, 2001, 98, 41–48.

    Gertz M. A. , 'Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglubulinemia: results of United States intergroup trial (Southwest Oncology Group S9003) ' (2001 ) 98 Blood : 41 -48.

    • Search Google Scholar
  • Dhodapkar, M. V., Jakobson, J. L., Gertz, M. A., et al.: Prognostic factors and response to fludarabine therapy in Waldenstrom’s macroglubulinemia: an update of a US Intergroup trial (SWOG S9003). Semin. Oncol., 2003, 30, 220–225.

    Gertz M. A. , 'Prognostic factors and response to fludarabine therapy in Waldenstrom’s macroglubulinemia: an update of a US Intergroup trial (SWOG S9003) ' (2003 ) 30 Semin. Oncol. : 220 -225.

    • Search Google Scholar
  • Dimopoulos, M. A., Hamilos, G., Efstathiou, E., et al.: Treatment of Waldenstrom’s macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk. Lymphoma, 2003, 44, 993–996.

    Efstathiou E. , 'Treatment of Waldenstrom’s macroglobulinemia with the combination of fludarabine and cyclophosphamide ' (2003 ) 44 Leuk. Lymphoma : 993 -996.

    • Search Google Scholar
  • Tam, C. S., Wolf, M. M., Westerman, D., et al.: Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström’s macroglobulinemia. Clin. Lymphoma Myeloma, 2005, 6, 136–139.

    Westerman D. , 'Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström’s macroglobulinemia ' (2005 ) 6 Clin. Lymphoma Myeloma : 136 -139.

    • Search Google Scholar
  • Dhodapkar, M. V., Hoering, A., Gertz, M. A., et al.: Long-term survival in Waldenstrom macroglubulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood, 2009, 113, 793–796.

    Gertz M. A. , 'Long-term survival in Waldenstrom macroglubulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003 ' (2009 ) 113 Blood : 793 -796.

    • Search Google Scholar
  • Gertz, M. A., Abonour, R., Heffner, L. T., et al.: Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br. J. Haematol., 2009, 147, 677–680.

    Heffner L. T. , 'Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial ' (2009 ) 147 Br. J. Haematol. : 677 -680.

    • Search Google Scholar
  • Dimopoulos, M. A., Anagnostopoulos, A., Kyrtsonis, M. C., et al.: Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J. Clin. Oncol., 2007, 25, 3344–3349.

    Kyrtsonis M. C. , 'Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide ' (2007 ) 25 J. Clin. Oncol. : 3344 -3349.

    • Search Google Scholar
  • Tedeschi, A., Benevolo, G., Varettoni, M., et al.: Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia. An effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer, 2012, 118, 434–443.

    Varettoni M. , 'Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia. An effective but myelosuppressive regimen to be offered to patients with advanced disease ' (2012 ) 118 Cancer : 434 -443.

    • Search Google Scholar
  • Treon, S. P., Branagan, A. R., Ioakimidis, L., et al.: Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood, 2009, 113, 3673–3678.

    Ioakimidis L. , 'Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia ' (2009 ) 113 Blood : 3673 -3678.

    • Search Google Scholar
  • Ghobrial, I. M., Hong, F., Padmanabhan, S., et al.: Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenström macroglobulinemia. J. Clin. Oncol., 2010, 28, 1422–1428.

    Padmanabhan S. , 'Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenström macroglobulinemia ' (2010 ) 28 J. Clin. Oncol. : 1422 -1428.

    • Search Google Scholar
  • Kyriakou, C., Canals, C., Sibon, D., et al.: High-dose therapy and autologous stem-cell transplantation in Waldenström macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J. Clin. Oncol., 2010, 28, 2227–2232.

    Sibon D. , 'High-dose therapy and autologous stem-cell transplantation in Waldenström macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation ' (2010 ) 28 J. Clin. Oncol. : 2227 -2232.

    • Search Google Scholar
  • Kyriakou, C., Canals, C., Cornelissen, J. J., et al.: Allogeneic stem-cell transplantation in patiens with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J. Clin. Oncol., 2010, 28, 4926–4934.

    Cornelissen J. J. , 'Allogeneic stem-cell transplantation in patiens with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation ' (2010 ) 28 J. Clin. Oncol. : 4926 -4934.

    • Search Google Scholar
  • Treton, S. P.: XIII. Waldenström’s macroglobulinaemia: an indolent B-cell lymphoma with distinct molecular and clinical features. Hematol. Oncol., 2013, 31 (Suppl. 1), 76–80.

    Treton S. P. , 'XIII. Waldenström’s macroglobulinaemia: an indolent B-cell lymphoma with distinct molecular and clinical features ' (2013 ) 31 Hematol. Oncol. : 76 -80.

    • Search Google Scholar
  • Rummel, M. J., et al.: Bendamustine plus rituximab compared to R-CHOP as first-line treatment in advanced follicular, indolent, and mantle cell lymphomas. ASH 2009, Abstract 405.

  • Sacco, A., Leleu, X., Rossi, G., et al.: Novel agents in Waldenström Macroglobulinemia. Open J. Hematol., 2010 May 28, 1, 2.

    Rossi G. , 'Novel agents in Waldenström Macroglobulinemia ' (2010 ) 1 Open J. Hematol. : 2 -.

    • Search Google Scholar
  • Leleu, X., Gay, J., Roccaro, A. M., et al.: Update on therapeutic options in Waldenström macroglobulinemia. Eur. J. Haematol., 2009, 82, 1–12.

    Roccaro A. M. , 'Update on therapeutic options in Waldenström macroglobulinemia ' (2009 ) 82 Eur. J. Haematol. : 1 -12.

    • Search Google Scholar